Canagliflozin Hemihydrate
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Canagliflozin Hemihydrate is a pharmaceutical intermediate serving as the hemihydrated form of an SGLT2 inhibitor. It is synthesized via multi-step organic reactions involving glycosylation and functional group modifications. The compound features the molecular formula C16H19O8Na·0.5H2O (CAS No. 1048177-35-8) and is characterized by high purity for API manufacturing.</p>
<h3>Application</h3>
<ul>
<li><strong>Pharmaceutical Manufacturing:</strong> Primary raw material for producing oral tablets targeting Type 2 Diabetes Mellitus.</li>
<li><strong>Research & Development:</strong> Used in clinical trials to evaluate efficacy on renal glucose reabsorption inhibition.</li>
<li><strong>Quality Control:</strong> Standard reference substance for analytical method validation in GMP laboratories.</li>
</ul>
<h3>Precautions</h3>
<p>Storage requires controlled temperatures between 2°C and 8°C in sealed, moisture-proof containers to prevent hydration changes. Handling mandates PPE including gloves and goggles due to potential irritant properties. Clinical use is restricted for patients with severe renal impairment or those on dialysis.</p>